“By combining our groundbreaking isotope production capabilities, our team’s expertise and infrastructure with Lilly’s pharmaceutical and oncology expertise and global scale, we aim to bring ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...

AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, is expanding the scope and ...

Australian clinical-stage radiopharmaceutical company AdvanCell has announced an expansion to the scope and breadth of its ...

Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I ...

For two decades, Oncology on Canvas® has provided people in the cancer ... The program, a partnership between Lilly, the National Coalition for Cancer Survivorship and the Cancer Support Community, ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

after our adjusting our long-term earnings growth rate assumptions considering Lilly's broad portfolio in cardiometabolic, oncology, and immunology. Mounjaro and Zepbound are supporting solid ...

Since joining Lilly in 2022, Winselow has served as Group Vice President and Chief Commercial Officer of Lilly Oncology.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.